Sotera Health (SHC) EBITDA Margin (2020 - 2026)

Sotera Health (SHC) has reported EBITDA Margin for 7 consecutive years, with 3.74% the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA Margin rose 157.0% year-over-year to 3.74%; the TTM figure through Mar 2026 stood at 15.25% (up 1929.0% YoY), while the FY2025 annual figure was 15.16%, up 2162.0% from the prior year.
• EBITDA Margin came in at 3.74% for Q1 2026 at Sotera Health, down from 16.65% in the prior quarter.
• The five-year high for EBITDA Margin was 30.28% in Q2 2025, with the low at 104.29% in Q4 2022.
• Average EBITDA Margin over 5 years is 2.43%, with a median of 2.18% recorded in 2025.
• Across the five-year window, EBITDA Margin slumped 12871 bps in 2022 and soared 12367 bps in 2023, its largest moves.
• Year by year, EBITDA Margin stood at 104.29% in 2022, then surged by 119 bps to 19.38% in 2023, then sank by 227 bps to 24.57% in 2024, then soared by 168 bps to 16.65% in 2025, then plunged by 78 bps to 3.74% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 3.74%, 16.65%, and 10.02% for Q1 2026, Q4 2025, and Q3 2025 respectively.